D. Rangachari

发表

Moving From Theory to Practice in Oncology Education When Virtual Is Your Reality.

A. Im, Sam Brondfield, D. Rangachari, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

D. Costa, E. Wong, E. Uhlmann, 2015, Lung cancer.

Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform.

C. Lovly, J. Gilbert, E. Henry, 2021, JCO oncology practice.

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2021, Cells.

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

S. Kobayashi, D. Costa, M. Fujii, 2020, JTO clinical and research reports.

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

Page Widick, D. Costa, R. Gill, 2021, JAMA network open.

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, J. Shrager, 2021, JCO precision oncology.

A Veteran Presenting With Altered Mental Status and Clonus.

Anthony C Breu, D. Rangachari, B. Schlechter, 2020, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

D. Costa, X. Le, D. Rangachari, 2017, Journal of thoracic disease.

Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2020, The oncologist.

Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival

J. Cameron, T. Pawlik, R. Hruban, 2011, Journal of Gastrointestinal Surgery.

Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.

D. Costa, D. Rangachari, P. VanderLaan, 2018, Clinical lung cancer.

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

D. Costa, E. Folch, D. Rangachari, 2016, Cancer treatment communications.

Clinical coaching: Evolving the apprenticeship model for modern housestaff

L. Brown, D. Kern, D. Rangachari, 2017, Medical teacher.

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

D. Costa, G. Weiss, R. Gill, 2020, Clinical Lung Cancer.

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.

D. Costa, D. Rangachari, A. Varkaris, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The rapidly evolving landscape of biomarker testing in non–small cell lung cancer

D. Costa, D. Rangachari, P. VanderLaan, 2020, Cancer cytopathology.

Twelve tips for teaching oncology to non-oncologists

A. Hale, Daniel N. Ricotta, J. Freed, 2020, Medical teacher.

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature

D. Rangachari, R. Patell, R. Hallowell, 2019, Respiratory medicine case reports.

Safety and Efficacy of PD‐1 Inhibitors Among HIV‐Positive Patients With Non–Small Cell Lung Cancer

D. Costa, F. Marty, M. Cheng, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.

D. Costa, D. Rangachari, P. VanderLaan, 2018, Cancer treatment and research communications.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

D. Leaf, D. Iberri, Douglas B. Johnson, 2019, American journal of hematology.

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.

S. Kobayashi, D. Costa, D. Rangachari, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oncology Fellows' Clinical Discussions, Perceived Knowledge, and Formal Training Regarding Medical Cannabis Use: A National Survey Study

M. Schonberg, I. Braun, M. Buss, 2022, JCO oncology practice.

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

D. Costa, D. Rangachari, M. Shea, 2016, Therapeutic advances in respiratory disease.

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.

D. Costa, D. Rangachari, R. Patell, 2018, Translational cancer research.

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

D. Costa, Siraj M. Ali, K. Gowen, 2017, Lung cancer.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.

D. Costa, D. Rangachari, M. L. Peters, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.